Detail akcie Novavax Rg online

Business Summary: Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Novavax Inc revenues increased from $93.9M to $666.7M. Net income totaled $518.6M vs. loss of $147.6M. Revenues reflect Net product sales increase from $82.3M to $621.7M, Licensing Royalties And Other increase from $11.5M to $45M. Net Income reflects Biotechnology segment income totaling $515.5M vs. loss of $144.8M.